November 12, 2025

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice of the Establishment of CVC Fund "TOHO Ventures"

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro, hereinafter "TOHO HOLDINGS") is pleased to announce the establishment of the CVC Fund (the "Fund") jointly with Global Brain Corporation (Headquarters: Tokyo; President & CEO: Yasuhiko Yurimoto, hereinafter "Global Brain").

1. Background and Purpose of Establishment

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

In recent years, the healthcare industry has entered a period of significant transformation, driven by the advancement of drug discovery technologies, the progress of personalized medicine, the utilization of digital technologies, and the sophistication of supply chains. In this environment, TOHO HOLDINGS established the Fund to strengthen the search for seeds that will lead to the co-creation of new value in collaboration with innovative external companies.

The Fund primarily invests in advanced overseas startups, focusing on drug discovery and biotechnology sectors and medical DX. We will focus on supporting next-generation platforms that dramatically enhance drug discovery productivity through technological innovations in AI, data science, and cellular and genetic engineering, as well as new modalities enabling fundamental disease treatment. Furthermore, the Fund will actively leverage TOHO HOLDINGS' assets, including its pharmaceutical distribution network, dispensing pharmacy channels, and manufacturing and data infrastructure, to operate as a collaborative CVC that facilitates the commercialization and societal implementation of portfolio companies' businesses.

2. Overview of fund

Fund Name	TOHO Ventures （TOHO-GB Global Life Science Fund, L.P.）
Total AUM	10 billion yen
Fund Term	10 years
Investment Focus	Drug Discovery, Medical Devices, etc.
General Partner	Global Brain Corporation
Limited Partner	TOHO HOLDINGS CO.,LTD.

3. Overview of Global Brain

Company name	Global Brain Corporation
Location	2-17-1 Shibuya, Shibuya-ku, Tokyo 150-0002, JAPAN
Representative	Yasuhiko Yurimoto, President & CEO
Established	January 1998
Business content	Venture Capital Business
URL	https://globalbrains.com

4. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to increase the Group’s corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.